Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 1997

View Archived Issues

Update on Neurogen's schizophrenia program

Sugen and Hoechst Marion Roussel enter cancer drug research agreement

Cytel reports potent immunostimulant useful in vaccine development

Aricept launched in U.K.

U.K. launch for Campto

Naropin introduced in Germany

Novartis prepares novel signal transduction inhibitors

Factor Xa inhibitors from Boehringer Mannheim

BASF describes new glutamate antagonists

Inhibitors of ICE and ICE-like proteins claimed by SmithKline Beecham

KREATECH and Saliva Diagnostic Systems receive grant for TB test

Morinaga Milk claims new antiparasitic agents

Positive phase I data reported for liposomal PGE1 product for erectile dysfunction

Natural antifungal/antitumor agents discovered by Fujisawa

Estrogen receptor structure elucidated

Cholecystokinin antagonists for pancreatic disorders described by Tanabe

Anti-CD44 antisense oligonucleotides prepared by ICN

MEDI-507 heads for clinical trials

LeukoScan introduced yesterday in Germany

Quantison enters phase II trials

New MMP inhibitor disclosed by Agouron

Warner-Lambert describes new dopamine D4 antagonists

Synergistic benefit of citicoline and NMDA antagonist shown in animal models of stroke

NitroMed and Cordis collaborate to develop novel cardiovascular products

Ergo Science and Massachusetts General Hospital conclude licensing agreement

Royce Laboratories' generic antiinflammatory approved by FDA

PDT expands phase II/III trial of Purlytin

Watson and Royce Laboratories merge

ImmuCell to initiate clinical trial of DiffGAM

Atorvastatin available in Germany for hyperlipidemia

Alteon reports positive results from phase II trials with pimagedine

Zagam available in Germany

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...